research use only
Cat.No.S6593
| Related Targets | PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other Immunology & Inflammation related Inhibitors | Cl-amidine Bestatin (Ubenimex) Bindarit (AF 2838) Tempol Tranilast GI254023X (GI4023) Sinomenine Geniposidic acid CORM-3 Germacrone |
|
In vitro |
DMSO
: 100 mg/mL
(201.39 mM)
Water : 100 mg/mL Ethanol : 100 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 496.53 | Formula | C26H33NaO8 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2375-03-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | U-9088, 6α-Methylprednisolone 21-hemisuccinate Sodium | SMILES | CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)[O-])O.[Na+] | ||
Read more about storage stability stock solution CAS number SMILES
(data from https://clinicaltrials.gov, updated on 2026-07-30)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07072585 | NOT_YET_RECRUITING | Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma |
Children's Oncology Group |
2026-08-28 | PHASE2; PHASE3 |
| NCT07605923 | NOT_YET_RECRUITING | ACL Reconstruction |
University of Alabama at Birmingham |
2026-09 | PHASE4 |
| NCT07478003 | RECRUITING | STEMI - ST Elevation Myocardial Infarction |
Thomas Engstrom |
2026-04-20 | PHASE3 |
| NCT04127578 | ACTIVE_NOT_RECRUITING | Parkinson Disease |
Prevail Therapeutics |
2020-01-03 | PHASE1; PHASE2 |
| NCT06892210 | RECRUITING | Chronic Obstructive Pulmonary Disease (COPD) |
Copenhagen Respiratory Research |
2026-03-10 | PHASE4 |
| NCT04305145 | ACTIVE_NOT_RECRUITING | Melanoma Stage III; Melanoma Stage IV; Skin Cancer Stage III; Skin Cancer Stage IV; Drug-Induced Colitis; Drug Toxicity; Immune-related Adverse Event |
Massachusetts General Hospital |
2020-08-31 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.